Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin.

Shinichi KakoAyumi GomyoYu AkahoshiNaonori HaradaKazuaki KamedaTomotaka UgaiHidenori WadaYuko IshiharaKoji KawamuraKana SakamotoMiki SatoKiriko Terasako-SaitoShun-Ichi KimuraMisato KikuchiHideki NakasoneJunya KandaYoshinobu Kanda

Published in: European journal of haematology (2019)

Haploidentical HSCT using low-dose alemtuzumab can be performed safely. We need to overcome the high relapse/progression rate in non-remission patients.

Keyphrases

low dose
stem cell transplantation
high dose
bone marrow
end stage renal disease
peripheral blood
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
cell therapy
stem cells
mesenchymal stem cells
disease activity
clinical evaluation